Physician profile
Joseph Trapasso
NPI 1912996281
$1,859.73
in general payments reported to CMS, 2019-2025
17 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $12.95 · 2021: $64.60 · 2022: $249 · 2023: $262 · 2024: $194 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $930 · Food and Beverage: $456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $930.00 |
| Food and Beverage | $456.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $930.00 | 2025 | Imfinzi |
| Axonics, INC. | $176.24 | 2021-2023 | Axonics |
| Ethicon US, LLC | $147.25 | 2019 | |
| Abbvie INC. | $107.36 | 2023-2024 | Botox |
| Intuitive Surgical, INC. | $105.17 | 2020-2024 | |
| Medtronic, INC. | $100.00 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $76.48 | 2023-2024 | Gemtesa |
| Dentsply Ih INC. | $35.61 | 2022 | |
| Dentsply Ih Ab | $35.42 | 2023 | Lofric |
| Ambu INC. | $24.15 | 2022 | |
| Urovant Sciences INC | $23.98 | 2022 | |
| Conmed Corporation | $20.61 | 2023 | Airseal |
| Astellas Pharma US INC | $18.47 | 2023 | Xtandi |
| Mission Pharmacal Company | $17.58 | 2022 | |
| Myovant Sciences INC. | $15.37 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13.94 | 2024 | |
| Integra Lifesciences Corporation | $12.10 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Trapasso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.